Hantz Financial Services Inc. Sells 1,204 Shares of Stryker Corporation $SYK

Hantz Financial Services Inc. cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 8.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,123 shares of the medical technology company’s stock after selling 1,204 shares during the quarter. Hantz Financial Services Inc.’s holdings in Stryker were worth $5,192,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in SYK. Vanguard Group Inc. lifted its holdings in shares of Stryker by 1.1% in the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after buying an additional 361,136 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Stryker by 13.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after buying an additional 261,058 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Stryker by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock worth $776,871,000 after buying an additional 83,954 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Stryker by 1.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock worth $750,223,000 after buying an additional 30,329 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Down 0.1%

Shares of NYSE SYK opened at $369.31 on Friday. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm’s 50 day simple moving average is $378.83 and its two-hundred day simple moving average is $380.54. The stock has a market capitalization of $141.19 billion, a P/E ratio of 48.92, a PEG ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter last year, the business earned $2.87 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale is available in the SEC filing. 5.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on SYK shares. Evercore ISI lowered their target price on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Wells Fargo & Company raised their target price on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Rothschild Redb raised shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Needham & Company LLC raised their target price on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Finally, Truist Financial lowered their target price on shares of Stryker from $415.00 to $407.00 and set a “hold” rating on the stock in a research note on Wednesday, October 15th. Thirteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $434.32.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.